PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202633	CFT-1297	2154353-03-2	CRBN	BRD4	Inquiry
Molecular Weight: 824.43 Molecular Formula: C47H50ClN9O3 Density: 1.43±0.1 g/cm3 Description: CFT-1297 is a BRD4 degrader by conjugation of the E3 ligase CRBN and the first bromodomain of BRD4, a prominent oncology target.
	BPL-202634	SAB355	2763367-27-5	CRBN	CDK4 CDK6	Inquiry
Molecular Weight: 936.04 Molecular Formula: C47H57N11O10 Density: 1.382±0.06 g/cm3 Description: It is a heterodimeric CRBN-based degrader that induces the degradation of CDK4 and CDK6.
	BPL-202635	SAB401	2763367-28-6	CRBN	CDK4 CDK6	Inquiry
Molecular Weight: 964.05 Molecular Formula: C48H57N11O11 Density: 1.385±0.06 g/cm3 Description: It is a heterodimeric CRBN-based degrader that induces the degradation of CDK4 and CDK6.
	BPL-202636	CST837	2763367-29-7	CRBN	CDK4 CDK6	Inquiry
Molecular Weight: 994.08 Molecular Formula: C49H59N11O12 Density: 1.380±0.06 g/cm3 Description: It is a heterodimeric CRBN-based degrader that induces the degradation of CDK4 and CDK6.
	BPL-202637	4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)-2-fluorobenzamide	2766579-48-8	CRBN	AR	Inquiry
Molecular Weight: 837.81 Molecular Formula: C39H35F4N7O8S Density: 1.54±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202638	4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)-2-fluorobenzamide	2766579-49-9	CRBN	AR	Inquiry
Molecular Weight: 881.86 Molecular Formula: C41H39F4N7O9S Density: 1.52±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202639	4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-fluorobenzamide	2766579-50-2	CRBN	AR	Inquiry
Molecular Weight: 805.81 Molecular Formula: C39H35F4N7O6S Density: 1.51±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202640	4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-2-fluorobenzamide	2766579-51-3	CRBN	AR	Inquiry
Molecular Weight: 833.87 Molecular Formula: C41H39F4N7O6S Density: 1.48±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202641	4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decyl)-2-fluorobenzamide	2766579-52-4	CRBN	AR	Inquiry
Molecular Weight: 861.92 Molecular Formula: C43H43F4N7O6S Density: 1.45±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202642	4-(3-(4'-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-61-5	CRBN	AR	Inquiry
Molecular Weight: 868.89 Molecular Formula: C44H39F3N6O8S Density: 1.49±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202643	4-(3-(4'-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-62-6	CRBN	AR	Inquiry
Molecular Weight: 912.94 Molecular Formula: C46H43F3N6O9S Density: 1.47±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202644	4-(3-(4'-((6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)oxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-63-7	CRBN	AR	Inquiry
Molecular Weight: 836.89 Molecular Formula: C44H39F3N6O6S Density: 1.47±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202645	4-(3-(4'-((8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)oxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-64-8	CRBN	AR	Inquiry
Molecular Weight: 864.95 Molecular Formula: C46H43F3N6O6S Density: 1.43±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202646	4-(3-(4'-((10-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decyl)oxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-65-9	CRBN	AR	Inquiry
Molecular Weight: 892.99 Molecular Formula: C48H47F3N6O6S Density: 1.41±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202647	4-(3-(4-(1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)acetyl)piperidin-4-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-69-3	CRBN	AR	Inquiry
Molecular Weight: 873.91 Molecular Formula: C43H42F3N7O8S Density: 1.50±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202648	4-(3-(4-(1-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetyl)piperidin-4-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-70-6	CRBN	AR	Inquiry
Molecular Weight: 917.96 Molecular Formula: C45H46F3N7O9S Density: 1.48±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202649	4-(3-(4-(1-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperidin-4-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile		CRBN	AR	Inquiry
Molecular Weight: 841.91 Molecular Formula: C43H42F3N7O6S Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202650	4-(3-(4-(1-(8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octanoyl)piperidin-4-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-72-8	CRBN	AR	Inquiry
Molecular Weight: 869.97 Molecular Formula: C45H46F3N7O6S Density: 1.44±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202651	4-(3-(4-(1-(10-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decanoyl)piperidin-4-yl)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-73-9	CRBN	AR	Inquiry
Molecular Weight: 898.02 Molecular Formula: C47H50F3N7O6S Density: 1.41±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.
	BPL-202652	4-(3-(4'-((3-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)phenyl)prop-2-yn-1-yl)oxy)-[1,1'-biphenyl]-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile	2766579-76-2	CRBN	AR	Inquiry
Molecular Weight: 963.98 Molecular Formula: C52H40F3N7O7S Density: 1.54±0.1 g/cm3 Description: It is an enzalutamide-based PROTAC that can potently degrade androgen receptor (AR) in lung cancer cells.